Predictors of responses to immune checkpoint blockade in advanced melanoma
Nicolas Jacquelot(University of Calgary), Laurence Zitvogel(Institut Gustave Roussy), Brigitte Dréno(Nantes Université), Andressa L. Sodré(NYU Langone Health), Massimo Di Maïo(University of Siena), Sylvie Rusakiewicz(Inserm), Vijay K. Kuchroo(Broad Institute), Christophe Borg(Centre Hospitalier Universitaire de Besançon), Yaron Meirow(Concern Foundation), Ignacio Melero(University of Oxford), Mitchell P. Levesque(Duke University), Nils Ternès(Université Paris-Saclay), Dirk Schadendorf(National Center for Tumor Diseases), Lieping Chen(Yale Cancer Center), F. Aubin(Centre Hospitalier Universitaire de Besançon), Jeffrey S. Weber(NYU Langone Health), Meriem Messaoudene(Centre Hospitalier de l’Université de Montréal), Inge Marie Svane(Copenhagen University Hospital), Gorana Tomasic, Connie P.M. Duong(Peter MacCallum Cancer Centre), O. Beatrix(Université Claude Bernard Lyon 1), Moshe Sade-Feldman(Harvard University), Mark J. Smyth(Peter MacCallum Cancer Centre), Morten Hansen(Copenhagen University Hospital), Stefan Michiels(Institut Gustave Roussy), Henrik Schmidt(Aarhus University Hospital), Aurélien Marabelle(Institut Gustave Roussy), David Woods(Moffitt Cancer Center), Stéphane Dalle(Hospices Civils de Lyon), Lawrence Fong(UCSF Helen Diller Family Comprehensive Cancer Center), Michal Lotem(Hadassah Medical Center), Guido Kroemer(Institut Universitaire de France), Maha Ayyoub(Inserm), Michal Baniyash(Hebrew University of Jerusalem), Serena S. Kwek(University of California, San Francisco), Yoshinobu Koguchi(Providence Portland Medical Center), Andréa Cavalcanti(Institut Gustave Roussy), David Enot(Institut Gustave Roussy), Ana C. Anderson(Brigham and Women's Hospital), Reinhard Dummer(University Hospital of Zurich), Alexander Eggermont(University Medical Center Utrecht), Benjamin Weide(University Children's Hospital Tübingen), Byoung S. Kwon(Eilenburger Elektrolyse - und Umwelttechnik (Germany)), Anna Maria Di Giacomo(University of Siena), Sarah Jégou(Centre National de la Recherche Scientifique), María P. Roberti(Inserm), B. Balme(Université Claude Bernard Lyon 1), Caroline Flament(Inserm), Abhishek Burra(University of California, San Francisco), Amir Khammari(Inserm)
Cited by 201
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
|Science|2017|5.4k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
|Nature Medicine|2002|5k